Ibutamoren in online discussions and in the studies, in brief
MK-677, or ibutamoren, is described in MK-677 Reddit accounts through two early changes, increased appetite and deeper, dream-filled sleep within the first nights, while changes in lean body mass and strength are disputed and many accounts describe no effect at all. Controlled trials bear out part of that, recording more fat-free mass (body weight excluding fat).
The same studies measured MK 677 sleep quality too: more stage IV sleep (the deepest stage of non-REM sleep) and more REM sleep, the stage where dreaming is concentrated. Growth hormone (the pituitary hormone of growth and tissue repair) acts largely through IGF-1 (insulin-like growth factor 1), which rose in the trials, though strength and physical function did not improve; beyond them, published cases add changes in liver function tests, blood glucose and hormones that accounts outside the trials rarely mention.
We therefore set the ibutamoren experience described outside the trials beside what the studies and cases measured, without weighing the compound against others of its kind. What is MK 677 in pharmacological terms? An orally active growth hormone secretagogue, a molecule that prompts the pituitary gland to release more endogenous growth hormone, which places the compound in endocrinology rather than in androgen pharmacology.
What the controlled trials of ibutamoren measured in humans
A two-year randomised, placebo-controlled trial gave ibutamoren orally at 25 mg once daily to 65 healthy adults aged 60 to 81, and at twelve months fat-free mass had risen by 1.1 kg against a fall of 0.5 kg on placebo, body weight by 2.7 kg against 0.8 kg. The fat measures diverged, limb fat mass rising by 1.1 kg against 0.24 kg on placebo while total fat mass and abdominal visceral fat did not change, and the trial measured blood sugar on MK677 as well: fasting glucose rose by 0.3 mmol/L and insulin sensitivity (the responsiveness of tissues to insulin) fell, while LDL cholesterol (the fraction carried in low-density lipoprotein) fell and cortisol was higher.
The added fat-free mass did not improve isokinetic strength or physical function, and the most frequent adverse effects were a rise in appetite that subsided within a few months, transient mild lower-extremity oedema and pain in muscle tissue.
At the same daily amount, a phase IIb trial gave MK-0677 to 123 elderly patients after hip fracture: IGF-1 rose by 51.4 ng/ml and gait speed improved, most other functional measures did not, and the trial ended early on a safety signal bearing on MK-677 and the heart, congestive heart failure, an inability of the heart to pump enough blood. The same compound, developed for paediatric trials as LUM-201, outperformed standard stimulation tests in 68 children with growth hormone deficiency, a single dose given orally producing median growth hormone peaks of 15.0 ng/mL against 5.5 ng/mL with the standard tests.
Growth hormone secretagogues are described in review as generally well tolerated, with concern over rising blood glucose as insulin sensitivity falls, and a sports-medicine scoping review classed 67 per cent of publications on such compounds as preclinical animal work, found the human studies few and modest, and lists congestive heart failure and insulin resistance among the documented risks of MK 677.
Four published cases record harm beside the trials, a liver enzyme rise after MK-677 alone and three with SARMs present, and the ibutamoren effect on liver function they show is set out in its own article.
In hip fracture patients treated with 25mg/day MK-0677, the increase in plasma IGF-1 levels was not paralleled by improvement in most functional performance measures.
How quickly the trials recorded changes after a dose
The quickest change the trials recorded came in growth hormone, which rose measurably within the testing session itself after a single dose given orally to 68 children with growth hormone deficiency; among the effects that built up over days, sleep changed quickest. In eight young men, 25 mg at bedtime for seven days raised stage IV sleep by about 50 per cent and REM sleep by more than 20 per cent, and in six older adults aged 65 to 71 the same amount for fourteen days raised REM sleep by nearly half and shortened REM latency, the interval between sleep onset and the first period of REM sleep, deviations from normal sleep falling from 42 per cent under placebo to 8 per cent.
The two-year trial recorded the rise in appetite among its earliest effects and saw it subside within a few months; it assessed body composition only every six months, so it could not have detected any earlier change there. The onset of these changes is a separate measure from the half-life of MK-677, the time over which the concentration of the compound in the blood falls by half.
How long does it take for MK-677 to start working?
Among the effects described outside the trials, the time MK-677 takes to start working is put at the first night or two, as appetite rises sharply and sleep becomes deep and dream-filled, with grogginess the following morning, and those first nights open a sequence that the accounts describe as running over months, and in some accounts as never beginning at all, in this order:
First night or two: appetite rises sharply and sleep becomes deep and dream-filled, with grogginess the following morning.
First weeks that follow: fluid retention and a fuller face.
Much later: changes in muscle mass, strength or recovery, in some accounts only after many months of unbroken exposure.
Never, in a noticeable share of cases: no change appears at all, however long exposure runs, and in those cases doubt shifts from the compound to the identity and content of the material itself.
How many users say MK-677 works, and how many notice no effect?
The accounts that say MK-677 works form, in descriptions beyond the trials, the largest of three groups; a second group notices no effect whatever and a third calls MK677 hit-and-miss. No count of the three exists, but the split itself is plain: the largest group describes unmistakable hunger, heavy sleep and a visible change in fluid retention and concludes on that basis that the compound is worthwhile (the usual answer to the question ‘is MK 677 worth it’), while the second group, smaller but louder, calls the compound over-hyped, not worth it or useless.
Beyond the trial data, that second group doubts the material in hand or the length of exposure far more often than the compound itself, so the question of authenticity recurs steadily, and much of the argument turns out to be about the contents of bottles rather than about pharmacology.
How common is each side effect among users?
Accounts outside the published studies describe the side effects of ibutamoren as differing in how common each one is, and the effects fall into a consistent order, from the most frequent:
hunger, the most frequent by a wide margin
fluid retention, facial puffiness and swollen or stiff fingers
heavy, vivid dreams and morning grogginess, which some accounts describe as welcome and others as the reason exposure ended
joint pain and numbness or tingling in the hands, described mainly where exposure ran long
nipple sensitivity, low mood and daytime tiredness, described less often
Hunger and the early fluid retention have also been described as fading while exposure continued, joint pain, numbness and vivid dreams as persisting until exposure ended.
The general account of the compound, in those accounts and beyond the trial data, holds increased appetite to be the most frequent effect and describes it as easing over the first months, with mild MK-677 water retention in the lower limbs, hands and face next, together with transient pain in muscle tissue and joints; that fluid retention is the usual explanation for numbness or tingling in the hands, through compression of the nerve at the wrist, as in carpal tunnel syndrome, and these effects settle or reverse once exposure ends, glucose metabolism being the exception, its disturbance held to be the most persistent effect and to last for the whole period of exposure.
Does MK-677 stop working over time?
MK-677 is described, outside the trial record, as losing its effect on appetite first, so that the MK677 hunger that was overwhelming at the start becomes ordinary while exposure continues, and heavy sleep and vivid dreams as following the same course, strong at the outset and quieter later, while fluid retention settles at a steady level rather than resolving.
The most frequent side effects were an increase in appetite that subsided in a few months and transient, mild lower-extremity edema and muscle pain.
Accounts outside the published studies also describe MK-677 as losing none of its effect over time, with hunger as strong late in exposure as at the beginning, and whether a break in exposure restores any of these effects is disputed, accounts of stopping and restarting dividing between an opening stretch resembling the start of exposure and no difference at all.
How much ibutamoren the studies administered, and for how long
Almost every human study of ibutamoren gave the compound orally at 25 mg once daily: healthy older adults received ibutamorenum at that amount for two years and the hip-fracture patients for 24 weeks, and only the sleep crossover tested lower amounts, 5 mg and 25 mg at bedtime in young men over seven-day periods and 2 mg and then 25 mg in older adults over fourteen-day periods, so across these studies the MK677 dose ranged from 2 mg to 25 mg a day, over periods from seven days to two years.
The published case reports describe lower amounts or shorter exposures than those trials: 15 mg daily for five weeks alongside LGD-4033 in the measured case, two months of exposure in the case of transaminitis, 25 mg daily for three months alongside two other compounds in the diabetes case. None of these studies and cases was designed to compare one amount with another, so the human data hold no dose-response comparison. LGD-4033 is one of the selective androgen receptor modulators (SARMs).
How long should a cycle of MK-677 last?
Outside the published trials, MK 677 cycle length is described as unsettled, cycles running from a couple of weeks to many months and a share of accounts describing a continuous course with no break at all; whether very short courses produce any effect is argued at length, usually on the ground that the early changes in appetite and sleep say nothing about the changes that develop more slowly, and stopping and restarting divides the accounts between an opening stretch resembling the start of exposure and no difference at all.
Does MK-677 lower testosterone or shrink the testicles?
Co-administration of LGD-4033 and MK-677 increased body mass, lean mass and fat mass, while negatively impacting bone, serum lipids, liver enzymes, testosterone (total and free) and, probably, follicle-stimulating hormone.
MK-677 has not been shown to lower testosterone on its own, because the one published case with full before-and-after hormone panels is the combined case of the table, 15 mg of it with 10 mg of LGD-4033 daily for five weeks. There the total hormone fell 62.3 per cent and the free fraction 85.7 per cent, sex hormone-binding globulin (SHBG, the plasma protein that binds and transports it) fell 79.6 per cent, and follicle-stimulating hormone (the pituitary signal that drives sperm production in the testes) stayed below the clinical reference range during and after exposure, while the total, the free fraction and SHBG all returned to pre-exposure levels once exposure ended.
Testicular volume was measured in no published human study of ibutamoren alone among the sources we drew on, so the MK-677 effect on testosterone rests on the hormone markers of that single combined case. The mechanism argues against a direct androgen effect, since growth hormone secretagogues are described in review as acting through pulsatile growth hormone release that remains subject to negative feedback; the same review lists appetite, lean body mass, bone turnover and sleep among the reported effects of such compounds, with rising blood glucose as the main safety concern.
Markers that returned to baseline after exposure stopped
In every published case that continued measurement after exposure ended, most markers moved back towards their starting values. In the measured case nearly every variable returned to its pre-exposure value once exposure to the compounds ended, the exceptions being:
total fat mass
appendicular fat mass
bone area
total cholesterol
LDL cholesterol
That case is the only measured MK-677 before and after record of body composition, and in it the figures that reversed stand apart from those that did not.
The organ markers followed the same course: in the transaminitis case liver function tests returned to normal limits once exposure to the compound ended, and in the diabetes case HbA1c stood at 5.6 per cent a year after exposure to the compounds ended, far below the value at presentation. Reversal in a handful of patients does not establish reversal as a rule, since none of these cases was designed to follow its markers for long enough to establish one.
Do users keep their gains, and what happens after they stop?
In descriptions beyond the trials, the changes accumulated during exposure to MK-677 are kept only in part after exposure stops, because a large share of the added body weight is lost within the first weeks, as appetite falls quickly and sleep returns to baseline, while part of the added strength persists where resistance exercise continued; other accounts describe nothing retained at all and attribute the added weight to fluid retention from the outset, and reduced appetite and low energy for a short period after exposure ends appear in a smaller share of accounts, which most often call the compound overrated.
How can users tell if their MK-677 is real or underdosed?
A genuine batch of MK-677 is told apart from an underdosed one by four checks of the lot and its documentation, running from the number on the label to independent analysis of a sample. Outside the published trials, the accounts describe a single test instead, whether increased appetite and fluid retention appear within the first nights of exposure, material associated with neither change being called weak or a different compound altogether, and three further checks beside it: comparison with an earlier lot, the certificate that accompanied it and independent analysis of a sample.
In those accounts the four checks that tell real MK677 from an underdosed batch rest on the same documents and run as follows.
Find the batch number on the label: the label should carry a batch or lot number, because without one no certificate can be matched to the contents.
Match the certificate to that batch: batch number, compound name and date should agree between the container and its certificate of analysis, the document stating what a batch was found to contain.
Check how the batch was tested: the certificate should name the laboratory that tested the batch and its analytical method, such as high-performance liquid chromatography (HPLC), because a certificate lacking either carries nothing verifiable about the contents.
Send a sample for independent analysis: a sample goes to a third-party laboratory where the batch came without a certificate or where exposure to the material produced none of the early changes.
For laboratory research, you can buy MK 677 from us with a batch number and purity data on each certificate, as those accounts ask, and the same documentation accompanies the SARMs for sale in our shop.
Fear memory in a rat study of the ghrelin receptor
One animal finding bears on the questions of MK 677, mood and anxiety that recur outside the trials. In rats, repeated agonism of the ghrelin receptor, the receptor for the stomach-derived hunger hormone that is also the target of MK-677, enhanced fear memory, through growth hormone acting in the amygdala, the brain region that assembles fear responses; the rats were undergoing fear conditioning, so the finding is not a human endpoint, and it stands here only because flat mood and anxiety are so often described beyond the trial record.
Where ibutamoren stands with regulators and in sport
What the discussions never mention is the one regulatory decision on the compound, and it is narrow: it governs what a pharmacist may compound, not what ibutamoreno does. The US Food and Drug Administration (FDA) assessed the substance not as a supplement but as a bulk ingredient for pharmacy preparation and entered ibutamoren mesylate on its list of bulk drug substances that may present significant safety risks in compounding (a medicine prepared to order for an individual patient), naming potential congestive heart failure as the risk, for 503B outsourcing facilities from December 2022 and for 503A pharmacies from September 2023.
In sport, the compounds found beside ibutamoren in the case reports have a status of their own, set by the World Anti-Doping Agency (the body setting anti-doping rules for Olympic sport), whose 2026 prohibited list names andarine, LGD-4033 and RAD140, together with enobosarm, S-23 and YK-11, among the other anabolic agents of section S1.2 and bans all six at all times, in and out of competition.
[Figure 1. MK-677 from human trials to FDA listing. Human trials of ibutamoren from 1997 to 2022, set against the FDA’s listing of ibutamoren mesylate as a bulk substance that may present significant safety risks in compounding. The listing applies to 503B facilities from December 2022 and to 503A pharmacies from September 2023; it is neither an approval nor a ban.]
What these discussions cannot settle
Neither the descriptions outside the trials nor the controlled evidence settles how MK-677 acts in young trained adults: the only long placebo-controlled trial tested a single daily amount in healthy adults aged 60 to 81 and recorded no gain in strength or physical function, each published case describes a single patient, two of the four involved more than one compound, so none of them can be held responsible alone for the measured changes, and a scoping review found the human evidence on such compounds sparse and the claimed musculoskeletal benefits unsubstantiated.
Several effects are therefore known from description alone, in MK-677 Reddit accounts and the other discussions outside the trials: the intensity of the appetite increase, facial puffiness and swelling of the fingers, vivid dreams and morning grogginess, numbness or tingling in the hands, daytime tiredness, nipple sensitivity and the absence of any response. No published study among the sources we drew on has measured these effects, nor whether the early changes fade during exposure, how quickly body weight falls after exposure ends or how a batch comes to be judged genuine.
Important information. This article summarises published research and case reports, and notes where effects are described outside the published trials. It is not medical advice, and Max Muscle Labs does not give dosing guidance or any information implying human use. Many of the compounds discussed here are not approved for human use by the MHRA, the FDA or any other regulator, and many are prohibited in sport by WADA. Products sold by Max Muscle Labs are supplied strictly for laboratory and analytical research use and are not for human or veterinary consumption.
Check what you remember
4 questions on this article; the right answer is marked.
In the two-year trial of healthy adults aged 60 to 81, what accompanied the rise in fat-free mass?
Isokinetic strength rose in step with lean mass
Strength and physical function did not improve ✓
Abdominal visceral fat fell by about a kilogram
Gait speed and stair climbing both improved
Fat-free mass rose by 1.1 kg against a fall on placebo, yet strength and physical function stayed where they were.
Why did the phase IIb trial in elderly patients recovering from hip fracture end early?
A sharp rise in liver aminotransferases
Too many cases of overt diabetes appearing
A safety signal of congestive heart failure ✓
Recruitment fell short of the planned number
IGF-1 rose by 51.4 ng/ml, but the trial was stopped on a safety signal of congestive heart failure in some patients.
What did the sleep trials record in young men and in older adults?
More REM sleep, where dreaming is concentrated ✓
Less REM sleep and deeper, dreamless nights
A longer delay before the first period of REM sleep
No change in sleep stages, only more time asleep
REM sleep rose by more than 20 per cent in young men and by nearly half in older adults, and REM latency shortened.
What does the one case with hormone panels before, during and after exposure show about testosterone?
It fell for good and never returned to baseline
It fell on MK-677 alone and stayed low for months
It rose, because growth hormone drives androgen release
Its fall came alongside LGD-4033, not MK-677 alone ✓
The man was exposed to MK-677 together with LGD-4033 for five weeks; total testosterone fell 62.3 per cent and returned once exposure ended.
Nina Meyer is a specialist in internal medicine in the Department of Endocrinology and Metabolism at Charité Universitätsmedizin Berlin. Nina specialises in metabolic endocrinology and the growth hormone and IGF-1 axis.
Hongying Wang is a postdoctoral research associate in the Department of Nutrition at Texas A&M University. Hongying specialises in ghrelin receptor and GH secretagogue pharmacology.
RAD 140 before and after accounts report rises in body weight and strength, but no study has measured how much is muscle or what remains after exposure.
ostarine for cutting is untested in lean adults, but in a semaglutide weight-loss trial enobosarm cut lean-mass loss by 71% and raised fat loss by 27%.
What does RAD-140 do to the brain is known only from nerve-cell and rat studies, where it shielded neurons from injury about as well as testosterone did.
Hurry while stocks last! Use code PAYDAY15 at checkout to get 15% off sitewide. Valid for
Join the WaitlistWe will inform you when the product is back in stock. Enter your email address below.
MK-677 Reddit: discussions weighed against the trials
By Nina Meyer · Reviewed by Hongying Wang
Published · Updated · 17 min read
Ibutamoren in online discussions and in the studies, in brief
MK-677, or ibutamoren, is described in MK-677 Reddit accounts through two early changes, increased appetite and deeper, dream-filled sleep within the first nights, while changes in lean body mass and strength are disputed and many accounts describe no effect at all. Controlled trials bear out part of that, recording more fat-free mass (body weight excluding fat).
The same studies measured MK 677 sleep quality too: more stage IV sleep (the deepest stage of non-REM sleep) and more REM sleep, the stage where dreaming is concentrated. Growth hormone (the pituitary hormone of growth and tissue repair) acts largely through IGF-1 (insulin-like growth factor 1), which rose in the trials, though strength and physical function did not improve; beyond them, published cases add changes in liver function tests, blood glucose and hormones that accounts outside the trials rarely mention.
We therefore set the ibutamoren experience described outside the trials beside what the studies and cases measured, without weighing the compound against others of its kind. What is MK 677 in pharmacological terms? An orally active growth hormone secretagogue, a molecule that prompts the pituitary gland to release more endogenous growth hormone, which places the compound in endocrinology rather than in androgen pharmacology.
What the controlled trials of ibutamoren measured in humans
A two-year randomised, placebo-controlled trial gave ibutamoren orally at 25 mg once daily to 65 healthy adults aged 60 to 81, and at twelve months fat-free mass had risen by 1.1 kg against a fall of 0.5 kg on placebo, body weight by 2.7 kg against 0.8 kg. The fat measures diverged, limb fat mass rising by 1.1 kg against 0.24 kg on placebo while total fat mass and abdominal visceral fat did not change, and the trial measured blood sugar on MK677 as well: fasting glucose rose by 0.3 mmol/L and insulin sensitivity (the responsiveness of tissues to insulin) fell, while LDL cholesterol (the fraction carried in low-density lipoprotein) fell and cortisol was higher.
The added fat-free mass did not improve isokinetic strength or physical function, and the most frequent adverse effects were a rise in appetite that subsided within a few months, transient mild lower-extremity oedema and pain in muscle tissue.
At the same daily amount, a phase IIb trial gave MK-0677 to 123 elderly patients after hip fracture: IGF-1 rose by 51.4 ng/ml and gait speed improved, most other functional measures did not, and the trial ended early on a safety signal bearing on MK-677 and the heart, congestive heart failure, an inability of the heart to pump enough blood. The same compound, developed for paediatric trials as LUM-201, outperformed standard stimulation tests in 68 children with growth hormone deficiency, a single dose given orally producing median growth hormone peaks of 15.0 ng/mL against 5.5 ng/mL with the standard tests.
Growth hormone secretagogues are described in review as generally well tolerated, with concern over rising blood glucose as insulin sensitivity falls, and a sports-medicine scoping review classed 67 per cent of publications on such compounds as preclinical animal work, found the human studies few and modest, and lists congestive heart failure and insulin resistance among the documented risks of MK 677.
Four published cases record harm beside the trials, a liver enzyme rise after MK-677 alone and three with SARMs present, and the ibutamoren effect on liver function they show is set out in its own article.
How quickly the trials recorded changes after a dose
The quickest change the trials recorded came in growth hormone, which rose measurably within the testing session itself after a single dose given orally to 68 children with growth hormone deficiency; among the effects that built up over days, sleep changed quickest. In eight young men, 25 mg at bedtime for seven days raised stage IV sleep by about 50 per cent and REM sleep by more than 20 per cent, and in six older adults aged 65 to 71 the same amount for fourteen days raised REM sleep by nearly half and shortened REM latency, the interval between sleep onset and the first period of REM sleep, deviations from normal sleep falling from 42 per cent under placebo to 8 per cent.
The two-year trial recorded the rise in appetite among its earliest effects and saw it subside within a few months; it assessed body composition only every six months, so it could not have detected any earlier change there. The onset of these changes is a separate measure from the half-life of MK-677, the time over which the concentration of the compound in the blood falls by half.
How long does it take for MK-677 to start working?
Among the effects described outside the trials, the time MK-677 takes to start working is put at the first night or two, as appetite rises sharply and sleep becomes deep and dream-filled, with grogginess the following morning, and those first nights open a sequence that the accounts describe as running over months, and in some accounts as never beginning at all, in this order:
How many users say MK-677 works, and how many notice no effect?
The accounts that say MK-677 works form, in descriptions beyond the trials, the largest of three groups; a second group notices no effect whatever and a third calls MK677 hit-and-miss. No count of the three exists, but the split itself is plain: the largest group describes unmistakable hunger, heavy sleep and a visible change in fluid retention and concludes on that basis that the compound is worthwhile (the usual answer to the question ‘is MK 677 worth it’), while the second group, smaller but louder, calls the compound over-hyped, not worth it or useless.
Beyond the trial data, that second group doubts the material in hand or the length of exposure far more often than the compound itself, so the question of authenticity recurs steadily, and much of the argument turns out to be about the contents of bottles rather than about pharmacology.
How common is each side effect among users?
Accounts outside the published studies describe the side effects of ibutamoren as differing in how common each one is, and the effects fall into a consistent order, from the most frequent:
Hunger and the early fluid retention have also been described as fading while exposure continued, joint pain, numbness and vivid dreams as persisting until exposure ended.
The general account of the compound, in those accounts and beyond the trial data, holds increased appetite to be the most frequent effect and describes it as easing over the first months, with mild MK-677 water retention in the lower limbs, hands and face next, together with transient pain in muscle tissue and joints; that fluid retention is the usual explanation for numbness or tingling in the hands, through compression of the nerve at the wrist, as in carpal tunnel syndrome, and these effects settle or reverse once exposure ends, glucose metabolism being the exception, its disturbance held to be the most persistent effect and to last for the whole period of exposure.
Does MK-677 stop working over time?
MK-677 is described, outside the trial record, as losing its effect on appetite first, so that the MK677 hunger that was overwhelming at the start becomes ordinary while exposure continues, and heavy sleep and vivid dreams as following the same course, strong at the outset and quieter later, while fluid retention settles at a steady level rather than resolving.
Accounts outside the published studies also describe MK-677 as losing none of its effect over time, with hunger as strong late in exposure as at the beginning, and whether a break in exposure restores any of these effects is disputed, accounts of stopping and restarting dividing between an opening stretch resembling the start of exposure and no difference at all.
How much ibutamoren the studies administered, and for how long
Almost every human study of ibutamoren gave the compound orally at 25 mg once daily: healthy older adults received ibutamorenum at that amount for two years and the hip-fracture patients for 24 weeks, and only the sleep crossover tested lower amounts, 5 mg and 25 mg at bedtime in young men over seven-day periods and 2 mg and then 25 mg in older adults over fourteen-day periods, so across these studies the MK677 dose ranged from 2 mg to 25 mg a day, over periods from seven days to two years.
The published case reports describe lower amounts or shorter exposures than those trials: 15 mg daily for five weeks alongside LGD-4033 in the measured case, two months of exposure in the case of transaminitis, 25 mg daily for three months alongside two other compounds in the diabetes case. None of these studies and cases was designed to compare one amount with another, so the human data hold no dose-response comparison. LGD-4033 is one of the selective androgen receptor modulators (SARMs).
How long should a cycle of MK-677 last?
Outside the published trials, MK 677 cycle length is described as unsettled, cycles running from a couple of weeks to many months and a share of accounts describing a continuous course with no break at all; whether very short courses produce any effect is argued at length, usually on the ground that the early changes in appetite and sleep say nothing about the changes that develop more slowly, and stopping and restarting divides the accounts between an opening stretch resembling the start of exposure and no difference at all.
Does MK-677 lower testosterone or shrink the testicles?
MK-677 has not been shown to lower testosterone on its own, because the one published case with full before-and-after hormone panels is the combined case of the table, 15 mg of it with 10 mg of LGD-4033 daily for five weeks. There the total hormone fell 62.3 per cent and the free fraction 85.7 per cent, sex hormone-binding globulin (SHBG, the plasma protein that binds and transports it) fell 79.6 per cent, and follicle-stimulating hormone (the pituitary signal that drives sperm production in the testes) stayed below the clinical reference range during and after exposure, while the total, the free fraction and SHBG all returned to pre-exposure levels once exposure ended.
Testicular volume was measured in no published human study of ibutamoren alone among the sources we drew on, so the MK-677 effect on testosterone rests on the hormone markers of that single combined case. The mechanism argues against a direct androgen effect, since growth hormone secretagogues are described in review as acting through pulsatile growth hormone release that remains subject to negative feedback; the same review lists appetite, lean body mass, bone turnover and sleep among the reported effects of such compounds, with rising blood glucose as the main safety concern.
Markers that returned to baseline after exposure stopped
In every published case that continued measurement after exposure ended, most markers moved back towards their starting values. In the measured case nearly every variable returned to its pre-exposure value once exposure to the compounds ended, the exceptions being:
That case is the only measured MK-677 before and after record of body composition, and in it the figures that reversed stand apart from those that did not.
The organ markers followed the same course: in the transaminitis case liver function tests returned to normal limits once exposure to the compound ended, and in the diabetes case HbA1c stood at 5.6 per cent a year after exposure to the compounds ended, far below the value at presentation. Reversal in a handful of patients does not establish reversal as a rule, since none of these cases was designed to follow its markers for long enough to establish one.
Do users keep their gains, and what happens after they stop?
In descriptions beyond the trials, the changes accumulated during exposure to MK-677 are kept only in part after exposure stops, because a large share of the added body weight is lost within the first weeks, as appetite falls quickly and sleep returns to baseline, while part of the added strength persists where resistance exercise continued; other accounts describe nothing retained at all and attribute the added weight to fluid retention from the outset, and reduced appetite and low energy for a short period after exposure ends appear in a smaller share of accounts, which most often call the compound overrated.
How can users tell if their MK-677 is real or underdosed?
A genuine batch of MK-677 is told apart from an underdosed one by four checks of the lot and its documentation, running from the number on the label to independent analysis of a sample. Outside the published trials, the accounts describe a single test instead, whether increased appetite and fluid retention appear within the first nights of exposure, material associated with neither change being called weak or a different compound altogether, and three further checks beside it: comparison with an earlier lot, the certificate that accompanied it and independent analysis of a sample.
In those accounts the four checks that tell real MK677 from an underdosed batch rest on the same documents and run as follows.
For laboratory research, you can buy MK 677 from us with a batch number and purity data on each certificate, as those accounts ask, and the same documentation accompanies the SARMs for sale in our shop.
Fear memory in a rat study of the ghrelin receptor
One animal finding bears on the questions of MK 677, mood and anxiety that recur outside the trials. In rats, repeated agonism of the ghrelin receptor, the receptor for the stomach-derived hunger hormone that is also the target of MK-677, enhanced fear memory, through growth hormone acting in the amygdala, the brain region that assembles fear responses; the rats were undergoing fear conditioning, so the finding is not a human endpoint, and it stands here only because flat mood and anxiety are so often described beyond the trial record.
Where ibutamoren stands with regulators and in sport
What the discussions never mention is the one regulatory decision on the compound, and it is narrow: it governs what a pharmacist may compound, not what ibutamoreno does. The US Food and Drug Administration (FDA) assessed the substance not as a supplement but as a bulk ingredient for pharmacy preparation and entered ibutamoren mesylate on its list of bulk drug substances that may present significant safety risks in compounding (a medicine prepared to order for an individual patient), naming potential congestive heart failure as the risk, for 503B outsourcing facilities from December 2022 and for 503A pharmacies from September 2023.
In sport, the compounds found beside ibutamoren in the case reports have a status of their own, set by the World Anti-Doping Agency (the body setting anti-doping rules for Olympic sport), whose 2026 prohibited list names andarine, LGD-4033 and RAD140, together with enobosarm, S-23 and YK-11, among the other anabolic agents of section S1.2 and bans all six at all times, in and out of competition.
What these discussions cannot settle
Neither the descriptions outside the trials nor the controlled evidence settles how MK-677 acts in young trained adults: the only long placebo-controlled trial tested a single daily amount in healthy adults aged 60 to 81 and recorded no gain in strength or physical function, each published case describes a single patient, two of the four involved more than one compound, so none of them can be held responsible alone for the measured changes, and a scoping review found the human evidence on such compounds sparse and the claimed musculoskeletal benefits unsubstantiated.
Several effects are therefore known from description alone, in MK-677 Reddit accounts and the other discussions outside the trials: the intensity of the appetite increase, facial puffiness and swelling of the fingers, vivid dreams and morning grogginess, numbness or tingling in the hands, daytime tiredness, nipple sensitivity and the absence of any response. No published study among the sources we drew on has measured these effects, nor whether the early changes fade during exposure, how quickly body weight falls after exposure ends or how a batch comes to be judged genuine.
Check what you remember
4 questions on this article; the right answer is marked.
Fat-free mass rose by 1.1 kg against a fall on placebo, yet strength and physical function stayed where they were.
IGF-1 rose by 51.4 ng/ml, but the trial was stopped on a safety signal of congestive heart failure in some patients.
REM sleep rose by more than 20 per cent in young men and by nearly half in older adults, and REM latency shortened.
The man was exposed to MK-677 together with LGD-4033 for five weeks; total testosterone fell 62.3 per cent and returned once exposure ended.
Nina Meyer · Charité Berlin
Specialist in Internal Medicine
Nina Meyer is a specialist in internal medicine in the Department of Endocrinology and Metabolism at Charité Universitätsmedizin Berlin. Nina specialises in metabolic endocrinology and the growth hormone and IGF-1 axis.
Hongying Wang · Texas A&M University · Last reviewed
Postdoctoral Research Associate
Hongying Wang is a postdoctoral research associate in the Department of Nutrition at Texas A&M University. Hongying specialises in ghrelin receptor and GH secretagogue pharmacology.
Related Posts
RAD 140 before and after: muscle, strength and what lasts
RAD 140 before and after accounts report rises in body weight and strength, but no study has measured how much is muscle or what remains after exposure.
Ostarine for cutting: lean mass and fat loss in the trials
ostarine for cutting is untested in lean adults, but in a semaglutide weight-loss trial enobosarm cut lean-mass loss by 71% and raised fat loss by 27%.
RAD-140 Reddit: discussions set against the studies
RAD-140 Reddit accounts describe strength rising, hormone suppression and counterfeit products, set against the one human trial and case reports.
What does RAD-140 do to the brain? Neuron and rat studies
What does RAD-140 do to the brain is known only from nerve-cell and rat studies, where it shielded neurons from injury about as well as testosterone did.